Lundbeck Explores Xeris Biopharma Acquisition

Lundbeck A/S, a prominent Danish pharmaceutical company, is reportedly considering a significant acquisition. Sources familiar with the matter indicate that Lundbeck has expressed interest in taking over Xeris Biopharma Holdings Inc., a commercial-stage drugmaker. This exploration is currently being conducted with the assistance of financial advisers. Xeris Biopharma, headquartered in Chicago, operates within the competitive biopharmaceutical landscape. The potential deal signifies Lundbeck's strategic intent to expand its market presence and potentially integrate Xeris's commercial assets and drug pipeline. Discussions are ongoing, and the outcome remains subject to further developments and negotiations. The financial implications and specific terms of any potential transaction have not yet been disclosed.